FLT3 and acute myeloid leukemia: Evidence suggests that the epigenetic modulator, azacitidine (Aza), which is administered as an alternative to standard intensive chemotherapy in elderly patients with AML [16], does not upregulate FLT3 ligand and may in fact enhance the efficacy of FLT3 inhibitors [17, 18].